Development: VGV-S: Staphylococcus, Streptococcus And Sepsis

Our new VGV-S drug compound has been found to provide an alternative to traditional antibiotics in laboratory animals infected with Staphylococcus or with high levels of Streptococcus. Testing during 2009 determined that some infected mice treated with VGV-S, made full recoveries. A control group of sick animals that were not treated with this therapy either took much longer to recover or did not survive the infections.

The animal results of infection with these bacteria also suggest that VGV-S may have the potential to treat sepsis, a life-threatening systemic infection.

Like some of our other drug compounds, it is based on TPT discoveries made by Dr. Newell-Rogers and her team. Laboratory testing continues, both in the test tube and in animal studies, in preparation for possibly advancing this drug to human clinical trials.